Loading…
Listed Indian arm of AstraZeneca plc selling branded oncology, diabetes and respiratory drugs in India.
Listed Indian arm of AstraZeneca plc selling branded oncology, diabetes and respiratory drugs in India.
Markets its parent's patented medicines in India rather than discovering most of them itself, so launches depend on regulatory approvals and on what the parent chooses to bring to the Indian market. AstraZeneca plc holds a majority stake.
In one line: AstraZeneca's Indian pharma subsidiary.
Moat: narrow (brand, IP / patents). Access to AstraZeneca's global oncology and specialty pipeline, though the Indian entity is a small local unit.
Headquarters: Bengaluru, India · Founded: 1979 · Employees: 760
Size AstraZeneca Pharma India (ASTRAZEN.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.69B, the 417th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹6,374 on 6 Nov 2026.
Performance Over six months the shares fell 25.4%, against -4.2% for the median peer and 0.0% for the India market (cap-weighted) — 3rd lowest of 20 in its peer set.
Growth Revenue grew 31.1% over the last twelve months (peer median +10.9%); the operating margin is 9.9% (peer median 14.4%).
Valuation It trades at 6.5× enterprise value to sales against a peer median of 4.1× (7th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 49% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.7 points above its cost of capital (13.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹24.3B | ₹22.8B | ₹17.2B | ₹13.0B | ₹10.0B |
| Revenue growth | — | +33% | +32% | +29% | — |
| Gross profit | ₹6.31B | ₹5.94B | ₹4.43B | ₹4.32B | ₹3.55B |
| EBITDA | ₹2.58B | ₹2.66B | ₹2.58B | ₹1.87B | ₹1.67B |
| Net income | ₹1.70B | ₹1.88B | ₹1.16B | ₹1.62B | ₹993M |
| Free cash flow | n/a | ₹32.1M | ₹954M | ₹492M | ₹729M |
| Capital expenditure | n/a | ₹36.1M | ₹17.5M | ₹108M | ₹85.2M |
| Total debt | n/a | ₹1.11B | ₹357M | ₹45.9M | ₹72.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| AstraZeneca Pharma India ASTRAZEN.NS | $1.69B | -25% | +31% | 10% | 6.5× | 49.3% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | $4.53B | +2% | +12% | 33% | 9.8× | 25.2% |
| Novartis India NOVARTIND.NS | n/a | +67% | n/a | n/a | n/a | n/a |
| Pfizer PFIZER.NS | $1.87B | -19% | +12% | 34% | 5.5× | 11.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ASTRAZEN.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.7% | -1.0% | 6th highest of 21 |
| 6-month return | -25.4% | -4.2% | 3rd lowest of 20 |
| Distance from 52-week high | -35.3% | -29.7% | 9th lowest of 21 |
| Revenue growth (TTM) | +31.1% | +10.9% | 6th highest of 19 |
| Operating margin | 9.9% | 14.4% | 7th lowest of 19 |
| EV / Sales | 6.5× | 4.1× | 7th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 49.3% | 4.9% | most demanding of 13 |
| Growth delivered (Del g) | +23.0% | +10.4% | 3rd highest of 13 |
| Hurdle (Req g minus delivered) | +26.3 pp | -4.0 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | +6.7 pp | +1.5 pp | 9th highest of 20 |
| EV / EBITDA | 61.8× | 14.1× | 2nd most expensive of 9 |
| Net debt / EBITDA | -1.3× | -0.4× | 4th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharma India ASTRAZEN.NS | India | $1.69B | -25% | +31% | 10% | 6.5× | 49.3% | +23.0% |
| NATCO Pharma NATCOPHARM.NS | India | $1.68B | -30% | -21% | 25% | 4.5× | 15.3% | +19.0% |
| Braveheart Bio BRVE | United States | $1.67B | n/a | n/a | n/a | n/a | n/a | n/a |
| Yantai Dongcheng Biochemicals 002675.SZ | China | $1.67B | +1% | -4% | 15% | 4.7× | 6.7% | -4.3% |
| SELLAS Life Sciences SLS | United States | $1.70B | +68% | n/a | n/a | n/a | n/a | n/a |
| Shanghai Shyndec Pharmaceutical 600420.SS | China | $1.67B | -14% | -13% | 6% | 1.2× | -6.0% | -5.6% |
| Faes Farma FAE.MC | Spain | $1.71B | +5% | +32% | 14% | 2.6× | 3.1% | +9.9% |
| Consun Pharmaceutical 1681.HK | Hong Kong | $1.65B | +5% | +15% | 35% | 2.2× | -15.1% | +13.5% |
| Yifan Pharmaceutical 002019.SZ | China | $1.72B | -14% | -5% | 8% | 2.7× | n/a | n/a |
| Cohance Lifesciences COHANCE.NS | India | $1.75B | -11% | +41% | 6% | 7.7× | n/a | n/a |
| Mayinglong Pharmaceutical 600993.SS | China | $1.62B | -4% | +7% | 17% | 2.2× | -4.5% | +6.8% |
| Agios Pharmaceuticals AGIO | United States | $1.76B | +6% | +141% | -467% | 11.9× | n/a | n/a |
| Eton Pharmaceuticals ETON | United States | $1.61B | +236% | +81% | 16% | 15.3× | 39.6% | +359.6% |
| Beijing Aosaikang Pharmaceutical 002755.SZ | China | $1.76B | -25% | -13% | 12% | 5.9× | 14.7% | -14.0% |
| Zhejiang Wolwo Bio-Pharmaceutical 300357.SZ | China | $1.77B | -11% | +7% | 39% | 9.4× | 19.5% | +10.8% |
| JiangXi Tianxin Pharmaceutical 603235.SS | China | $1.60B | -5% | +16% | 24% | 3.7× | -4.1% | +0.2% |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | 18.4× | n/a | n/a |
| PharmaResearch 214450.KS | South Korea | $1.79B | -25% | +34% | 39% | 3.5× | -14.2% | +37.6% |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 1.7× | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 3.4× | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 9.6× | 37.6% | +16.6% |